| mRNA |
ML050 |
CTRPv2 |
pan-cancer |
AAC |
-0.004 |
0.9 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0033 |
0.9 |
| mRNA |
MK-0752 |
CTRPv2 |
pan-cancer |
AAC |
-0.0038 |
0.9 |
| mRNA |
ibrutinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0041 |
0.9 |
| mRNA |
alisertib |
CTRPv2 |
pan-cancer |
AAC |
-0.0029 |
0.9 |
| mRNA |
ML258 |
CTRPv2 |
pan-cancer |
AAC |
0.0032 |
0.9 |
| mRNA |
ML320 |
CTRPv2 |
pan-cancer |
AAC |
-0.003 |
0.9 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0024 |
0.9 |
| mRNA |
prochlorperazine |
CTRPv2 |
pan-cancer |
AAC |
-0.0028 |
0.9 |
| mRNA |
KU-60019 |
CTRPv2 |
pan-cancer |
AAC |
-0.0025 |
0.9 |